# OnCo record nct04957212 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04957212/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04957212", "NCT04957212" ;
  schema:name "P013 (CinnaGen pertuzumab) against Perjeta before surgery for HER2-positive breast cancer"@en ;
  schema:alternateName "P013 phase 3"@en, "IRCT20150303021315N11"@en ;
  schema:description "An Iranian phase 3 trial in which a locally made copy of pertuzumab gave the same rate of complete tumour disappearance before surgery as the original."@en ;
  schema:url <https://onco.cc/trials/nct04957212/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04957212>, <https://doi.org/10.1186/s12885-022-09895-5>, <https://pubmed.ncbi.nlm.nih.gov/36071409/> ;
  onco:status "completed" ;
  onco:phase "3" ;
  schema:startDate "2018-08-11" ;
  onco:cancers <https://onco.cc/cancers/breast-her2-positive/> ;
  onco:technologies <https://onco.cc/technologies/biosimilar-manufacturing/> ;
  onco:targets <https://onco.cc/targets/her2/> ;
  onco:drugs <https://onco.cc/drugs/pertuzumab/>, <https://onco.cc/drugs/trastuzumab/> ;
  onco:companies <https://onco.cc/companies/cinnagen/> ;
  onco:terms <https://onco.cc/terms/biosimilar/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-p013-pertuzumab-biosimilar-bmc-cancer-2022/> .